Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients
- 390 Downloads
AGM-130 is a cyclin-dependent kinase inhibitor that exhibits dose-dependent efficacy in xenograft mouse models. During preclinical pharmacokinetic (PK) studies, mice and rats showed comparable PK parameters while dogs showed unusually high clearance (CL), which has made human PK prediction challenging. To address this discrepancy, we performed a human microdosing PK and developed a mouse PK/PD model in order to guide the first-in-human studies.
A microdose of AGM-130 was given via intravenous injection to healthy subjects. Efficacy data obtained using MCF-7 breast cancer cells implanted in mice was analyzed using pre-existing tumor growth inhibition models. We simulated a human PK/PD profile with the PK parameters obtained from the microdose study and the PD parameters estimated from the xenograft PK/PD model.
The human CL of AGM-130 was 3.08 L/h/kg, which was comparable to CL in mice and rats. The time-courses of tumor growth in xenograft model was well described by a preexisting model. Our simulation indicated that the human doses needed for 50 and 90% inhibition of tumor growth were about 100 and 400 mg, respectively.
This is the first report of using microdose PK and xenograft PK/PD model to predict efficacious doses before the first-in-human trial in cancer patients. In addition, this work highlights the importance of integration of all of information in PK/PD analysis and illustrates how modeling and simulation can be used to add value in the early stages of drug development.
KeywordsHuman microdose Tumor growth inhibition AGM-130 Cyclin-dependent kinase Cancer
This research was supported by Anygen Co., Ltd.
Compliance with ethical standards
Conflict of interest
Sooho Ban, Moon-Young Park, San-ho Kim, Seon-Myung Kim and Yong-Chul Kim are employed by Anygen Co., Ltd. The other authors have no conflicts of interest to declare.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 6.Ahn MY, Kim TH, Kwon SM, Yoon HE, Kim HS, Kim JI, Kim YC, Kang KW, Ahn SG, Yoon JH (2015) 5-Nitro-5′-hydroxy-indirubin-3′-oxime (AGM130), an indirubin-3′-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo. Eur J Pharm Sci 79:122–131. doi: 10.1016/j.ejps.2015.08.015 CrossRefPubMedGoogle Scholar
- 8.Choi SJ, Lee JE, Jeong SY, Im I, Lee SD, Lee EJ, Lee SK, Kwon SM, Ahn SG, Yoon JH, Han SY, Kim JI, Kim YC (2010) 5,5′-substituted indirubin-3′-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem 53(9):3696–3706. doi: 10.1021/jm100080z CrossRefPubMedGoogle Scholar
- 10.FDA (2006) Guidance for industry, investigators, and reviewers: Exploratory IND studies. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf. Accessed 19 Jun 2017
- 11.Wong H, Gould SE, Budha N, Darbonne WC, Kadel EE 3rd, La H, Alicke B, Halladay JS, Erickson R, Portera C, Tolcher AW, Infante JR, Mamounas M, Flygare JA, Hop CE, Fairbrother WJ (2013) Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug Metab Dispos 41(12):2104–2113. doi: 10.1124/dmd.113.053926 CrossRefPubMedGoogle Scholar
- 13.Salphati L, Wong H, Belvin M, Bradford D, Ka Edgar, Wei W, Sampath D, Wallin JJ (2010) Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel PI3 K Inhibitor 2-(1 H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno [3, 2-d] pyrimidine (GDC-0941). Drug Metab Dispos 38(9):1436–1442. doi: 10.1124/dmd.110.032912 CrossRefPubMedGoogle Scholar
- 14.Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, Hop CECA, Gould SE (2012) Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18(14):3846–3855. doi: 10.1158/1078-0432.CCR-12-0738 CrossRefPubMedGoogle Scholar
- 17.Park MH, Lee YY, Cho KH, La S, Lee HJ, Yim DS, Ban S, Park MY, Kim YC, Kim YG, Shin YG (2016) Validation of a liquid chromatography-triple quadrupole mass spectrometric method for the determination of 5-nitro-5′-hydroxy-indirubin-3′-oxime (AGM-130) in human plasma and its application to microdose clinical trial. Biomed Chromatogr 30(3):323–329. doi: 10.1002/bmc.3551 CrossRefPubMedGoogle Scholar
- 22.Burt T, John CS, Ruckle JL, Vuong LT (2017) Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans—a practical guide. Expert Opin Drug Deliv 14(5):657–672. doi: 10.1080/17425247.2016.1227786 CrossRefPubMedGoogle Scholar